Please use this identifier to cite or link to this item: 10.3389/fneur.2020.586610
Title: Clinical Phenotyping and Biomarkers in Spinal and Bulbar Muscular Atrophy
Authors: Millere, Elīna
Rots, Dmitrijs
Glāzere, Ieva
Tauriņa, Gita
Kurjāne, Nataļja
Priedīte, Viktorija
Gailīte, Linda
Blennov, Kaj
Zetterberg, Henrik
Ķēniņa, Viktorija
Department of Doctoral Studies
Scientific Laboratory of Molecular Genetics
Department of Biology and Microbiology
Keywords: Kennedy disease;spinal and bulbar muscular atrophy;phenotype;clinical features;biomarker;Neurofilament;1.6 Biological sciences;3.2 Clinical medicine;1.1. Scientific article indexed in Web of Science and/or Scopus database
Issue Date: 20-Jan-2021
Citation: Millere , E , Rots , D , Glāzere , I , Tauriņa , G , Kurjāne , N , Priedīte , V , Gailīte , L , Blennov , K , Zetterberg , H & Ķēniņa , V 2021 , ' Clinical Phenotyping and Biomarkers in Spinal and Bulbar Muscular Atrophy ' , Frontiers in Neurology , vol. 11 , 586610 . https://doi.org/10.3389/fneur.2020.586610
Abstract: Background: Spinal and bulbar muscular atrophy (SBMA) or Kennedy disease [OMIM: 313200] is a rare X-linked neuromuscular disease. Patients commonly present with muscle cramps, tremors, leg weakness, dysarthria and dysphagia. Methods: We deeply phenotyped and evaluated the possible extent of affected systems in all patients with SBMA in Latvia (n = 5). In addition, neurophysiological studies and blood analyses were used to perform a molecular diagnosis and evaluate biochemical values. We analyzed neurofilament light (NfL) as a possible biomarker. Results: Neurological examination revealed typical SBMA clinical manifestations; all patients had small or large nerve fiber neuropathy. Three of five patients had increased neurofilament light levels. Conclusion: The study confirms the systemic involvement in patients suffering from SBMA. Increased NfL concentration was associated with either peripheral neuropathy or decreased body mass index. The complex phenotype of the disease should be kept in mind, as it could help to diagnose patients with SBMA.
Description: Funding Information: HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the UK Dementia Research Institute at UCL, and Riga Stradins University Internal grant No. 131005. Publisher Copyright: © Copyright © 2021 Millere, Rots, Glazere, Taurina, Kurjane, Priedite, Gailite, Blennow, Zetterberg and Kenina.
DOI: 10.3389/fneur.2020.586610
ISSN: 1664-2295
Appears in Collections:Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure

Files in This Item:


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.